PTCT Earnings
Latest Revenue360.5M
Latest Net Income83.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $1.01 | 360.5M | 83.5M | +101.5% | +221.7% |
| Q1 2026 | -$0.03 | 272.6M | -2809000 | -76.8% | -100.3% |
| Q4 2025 | -$1.62 | 164.7M | -134965000 | -22.7% | -90.6% |
| Q3 2025 | $0.20 | 211.0M | 15.9M | +7.2% | +114.4% |
| Q2 2025 | -$0.83 | 178.9M | -64849000 | -4.2% | +35.7% |
| Q1 2025 | $11.09 | 1.2B | 866.6M | +459.7% | +1,024.2% |
| Q4 2024 | -$0.85 | 213.2M | -65886000 | -30.6% | +58.7% |
| Q3 2024 | -$1.39 | 196.8M | -106654000 | +0.1% | +21.0% |
| Q2 2024 | -$1.29 | 186.7M | -99179000 | — | — |
| Q1 2024 | -$1.20 | 210.1M | -91576000 | — | — |
| Q4 2023 | -$2.06 | 307.1M | -155792000 | — | — |
| Q3 2023 | -$1.76 | 196.6M | -132970000 | — | — |
PTC Therapeutics (PTCT) — Earnings